Key result
Forced miR-144 expression protected against hyperglycemia-induced cardiac injury by improving mitochondrial biogenesis and decreasing cell apoptosis via targeting Rac-1.
Why the study?
MicroRNAs have potential as biomarkers for diabetic cardiomyopathy, but their specific functions in hyperglycemic cardiac dysfunction remain poorly understood.
Does miR-144 protect the heart from hyperglycemia-induced injury in models of diabetic cardiomyopathy?
Does miR-144 protect the heart from hyperglycemia-induced injury in models of diabetic cardiomyopathy?
MiR-144 protects against hyperglycemia-induced cardiac injury by improving mitochondrial biogenesis and reducing apoptosis, highlighting its potential as both a biomarker and therapeutic target for diabetic cardiomyopathy.
MiR-144 merits investigation as a modulator of mitochondrial biogenesis in diabetic cardiomyopathy; leaves open its role as a clinical biomarker or target.
Several lines of evidence have revealed the potential of microRNAs (miRNAs, miRs) as biomarkers for detecting diabetic cardiomyopathy, although their functions in hyperglycemic cardiac dysfunction are still lacking. In this study, mitochondrial biogenesis was markedly impaired induced by high glucose (HG), as evidenced by dysregulated mitochondrial structure, reduced mitochondrial DNA contents, and biogenesis-related mRNA levels, accompanied by increased cell apoptosis. MiR-144 was identified to be decreased in HG-induced cardiomyocytes and in streptozotocin (STZ)-challenged heart samples. Forced miR-144 expression enhanced mitochondrial biogenesis and suppressed cell apoptosis, while miR-144 inhibition exhibited the opposite results. Rac-1 was identified as a target gene of miR-144. Decreased Rac-1 levels activated AMPK phosphorylation and PGC-1α deacetylation, leading to increased mitochondrial biogenesis and reduced cell apoptosis. Importantly, the systemic neutralization of miR-144 attenuated mitochondrial disorder and ventricular dysfunction following STZ treatment. Additionally, plasma miR-144 decreased markedly in diabetic patients with cardiac dysfunction. The receiver-operator characteristic curve showed that plasma miR-144 could specifically predict diabetic patients developing cardiac dysfunction. In conclusion, this study provides strong evidence suggesting that miR-144 protects heart from hyperglycemia-induced injury by improving mitochondrial biogenesis and decreasing cell apoptosis via targeting Rac-1. Forced miR-144 expression might, thus, be a protective strategy for treating hyperglycemia-induced cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Tao et al. (2019) studied Diabetic cardiomyopathy. miR-144 expression vs. Control / miR-144 inhibition was evaluated on Mitochondrial biogenesis, cell apoptosis, and ventricular dysfunction. Forced miR-144 expression protected against hyperglycemia-induced cardiac injury by improving mitochondrial biogenesis and decreasing cell apoptosis via targeting Rac-1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: